The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 101–200 of 1,000
Patick, A. K., Mo, H., Markowitz, M., Appelt, K., Wu, B., Musick, L., Kalish, V, Kaldor, S., Reich, S., Ho, D., et al. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.292 · Cited by 209
Larder, B. A., Chesebro, B. W., & Richman, D. D. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.3.436 · Cited by 209
Self-citationProlonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex
Fischl, M. A. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430170067030 · Cited by 200
Kellam, P., & Larder, B. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.1.23 · Cited by 199
Self-citationFitzgibbon, J. E., Howell, R. M., Haberzettl, C. A., Sperber, S. J., Gocke, D. J., & Dubin, D. T. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.1.153 · Cited by 194
Harrigan, P. R., Bloor, S., & Larder, B. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.3773-3778.1998 · Cited by 193
Self-citationWhy does drug resistance readily evolve but vaccine resistance does not?
Kennedy, D. A., & Read, A. F. (2017) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2016.2562 · Cited by 192
Schooley, R. T., Merigan, T. C., Gaut, P., Hirsch, M. S., Holodniy, M., Flynn, T., Liu, S., Byington, R. E., Henochowicz, S., Gubish, E., et al. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-4-247 · Cited by 192
Meng, T.-C., Fischl, M. A., Boota, A. M., Spector, S. A., Bennett, D., Bassiakos, Y., Lai, S., Wright, B., & Richman, D. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-13 · Cited by 191
Self-citationKovacs, J. A., Deyton, L., Davey, R., Falloon, J., Zunich, K., Lee, D., Metcalf, J. A., Bigley, J. W., Sawyer, L. A., Zoon, K. C., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-280 · Cited by 191
Jacobsen, H., Yasargil, K., Winslow, D. L., Craig, J. C., Kröhn, A., Duncan, I. B., & Mous, J. (1995) · Virology · doi:10.1016/s0042-6822(95)80069-7 · Cited by 190
Ashorn, P., McQuade, T. J., Thaisrivongs, S., Tomasselli, A. G., Tarpley, W. G., & Moss, B. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7472 · Cited by 186
Murray, A. J., Kwon, K. J., Färber, D. L., & Siliciano, R. F. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600343 · Cited by 186
McLeod, G. X., & Hammer, S. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-487 · Cited by 182
Vella, S., Schwartländer, B., Sow, S. P., Eholie, S. P., & Murphy, R. L. (2012) · AIDS · doi:10.1097/qad.0b013e32835521a3 · Cited by 181
Tisdale, M., Myers, R. E., Maschera, B., Parry, N. R., Oliver, N. M., & Blair, E. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1704 · Cited by 180
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Xiao, Q., Guo, D., & Chen, S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00069 · Cited by 179
Boucher, C. A. B., Lange, J. M. A., Goudsmit, J., Mulder, J. W., Tersmette, M., de Goede, R. E. Y., Kellam, P., Darby, G., & Larder, B. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)93391-2 · Cited by 179
Self-citationPresent Status and Future Prospects for HIV Therapies
Johnston, M. I., & Hoth, D. F. (1993) · Science · doi:10.1126/science.7684163 · Cited by 179
Larder, B. A., Kemp, S. D., & Purifoy, D. J. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.13.4803 · Cited by 179
Self-citationJacobsen, H., Hänggi, M., Ott, M., Duncan, I. B. R., Owen, S., Andreoni, M., Vella, S., & Mous, J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.6.1379 · Cited by 179
Anthraquinones as a new class of antiviral agents against human immunodeficiency virus
Schinazi, R. F., Chu, C. K., Ramesh Babu, J., Oswald, B. J., Saalmann, V., Cannon, D. L., Eriksson, B. F. H., & Nasr, M. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90071-e · Cited by 178
Dueweke, T. J., Pushkarskaya, T., Poppe, S. M., Swaney, S. M., Zhao, J. Q., Chen, I. S., Stevenson, M., & Tarpley, W. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4713 · Cited by 178
Bender, A. R., von Briesen, H., Kreuter, J., Duncan, I. B. R., & Rübsamen‐Waigmann, H. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1467 · Cited by 177
Baba, M., De Clercq, E., Tanaka, H., Ubasawa, M., Takashima, H., Sekiya, K., Nitta, I., Umezu, K., Nakashima, H., & Mori, S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2356 · Cited by 176
Monocyte-derived macrophages contain persistent latent HIV reservoirs
Veenhuis, R. T., Abreu, C. M., Costa, P. A. G., Ferreira, E. A., Ratliff, J., Pohlenz, L., Shirk, E. N., Rubin, L. H., Blankson, J. N., Gama, L., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01349-3 · Cited by 175
The CD4-gpl20 Interaction and Aids Pathogenesis
Capon, D. J., & Ward, R. H. R. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.003245 · Cited by 174
Schinazi, R. F., Sommadossi, J. P., Saalmann, V, Cannon, D. L., Xie, M. Y., Hart, G. C., Smith, G. A., & Hahn, E. F. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1061 · Cited by 173
Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives
Balzarini, J. (1994) · Pharmacy World & Science · doi:10.1007/bf01880662 · Cited by 172
Götte, M., Arion, D., Parniak, M. A., & Wainberg, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3579-3585.2000 · Cited by 172
De Clercq, E. (1993) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60082-2 · Cited by 172
Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV
Goldberg, D. E., Siliciano, R. F., & Jacobs, W. R. (2012) · Cell · doi:10.1016/j.cell.2012.02.021 · Cited by 168
Debyser, Z., Pauwels, R., Andries, K., Desmyter, J., Kukla, M., Janssen, P. A., & De Clercq, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1451 · Cited by 168
Baicalin, an inhibitor of HIV-1 production in vitro
Kitamura, K., Honda, M., Yoshizaki, H., Yamamoto, S., Nakane, H., Fukushima, M., Ono, K., & Tokunaga, T. (1998) · Antiviral Research · doi:10.1016/s0166-3542(97)00069-7 · Cited by 168
Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase
Menéndez‐Arias, L. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.015 · Cited by 167
Latency in Human Immunodeficiency Virus Type 1 Infection: No Easy Answers
Persaud, D., Zhou, Y., Siliciano, J. M., & Siliciano, R. F. (2003) · Journal of Virology · doi:10.1128/jvi.77.3.1659-1665.2003 · Cited by 166
Larder, B. A. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-5-951 · Cited by 166
Self-citationBrowne, M. J., Mayer, K. H., Chafee, S. B. D., Dudley, M. N., Posner, M. R., Steinberg, S. M., Graham, K. K., Geletko, S. M., Zinner, S. H., Denman, S. L., et al. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.1.21 · Cited by 164
Molecular basis of human immunodeficiency virus drug resistance: An update
Menéndez-Arias, L. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.07.006 · Cited by 163
Therapy for Human Immunodeficiency Virus Infection
Wood, A. J. J., Hirsch, M. S., & D'Aquila, R. T. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306103282307 · Cited by 163
Nigranoic Acid, a Triterpenoid from Schisandra sphaerandra That Inhibits HIV-1 Reverse Transcriptase
Sun, H., Qiu, S., Lin, L.-Z., Wang, Z.-Y., Lin, Z., Pengsuparp, T., Pezzuto, J. M., Fong, H. H. S., Cordell, G. A., & Farnsworth, N. R. (1996) · Journal of Natural Products · doi:10.1021/np960149h · Cited by 163
Gao, Q., Gu, Z., Parniak, M. A., Li, X. G., & Wainberg, M. A. (1992) · Journal of Virology · doi:10.1128/jvi.66.1.12-19.1992 · Cited by 163
Balzarini, J., Pérez-Pérez, M. J., San-Félix, A., Schols, D., Perno, C. F., Vandamme, A. M., Camarasa, M. J., & De Clercq, E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4392 · Cited by 162
Nakashima, H., Masuda, M., Murakami, T., Koyanagi, Y., Matsumoto, A., Fujii, N., & Yamamoto, N. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.6.1249 · Cited by 162
Li, Y., Hui, H., Burgess, C. J., Price, R. W., Sharp, P. M., Hahn, B. H., & Shaw, G. M. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6587-6600.1992 · Cited by 161
Alpha‐1‐antitrypsin inhibits human immunodeficiency virus type 1
SHAPIRO, L., B. POTT, G., & H. RALSTON, A. (2001) · The FASEB Journal · doi:10.1096/fj.00-0311com · Cited by 161
Boyer, P. L., Tantillo, C., Jacobo‐Molina, A., Nanni, R. G., Ding, J., Arnold, E., & Hughes, S. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4882 · Cited by 161
Failure of Zidovudine Prophylaxis after Accidental Exposure to HIV-1
Lange, J. M. A., Boucher, C. A. B., Hollar, C. E. M., Wiltink, E. H. H., Reiss, P., van Royen, E. A., Roos, M., Danner, S. A., & Goudsmit, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005103221907 · Cited by 160
Marozsan, A. J., Kuhmann, S. E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B. M., Strizki, J., & Moore, J. P. (2005) · Virology · doi:10.1016/j.virol.2005.04.035 · Cited by 160
Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture
Larder, B. A., Coates, K. E., & Kemp, S. D. (1991) · Journal of Virology · doi:10.1128/jvi.65.10.5232-5236.1991 · Cited by 159
Self-citationKong, X., Zhu, Q. Y., Vidal, P. M., Watanabe, K. A., Polsky, B., Armstrong, D., Ostrander, M., Lang, S. A., Muchmore, E., & Chou, T. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.4.808 · Cited by 159
Richman, D., Rosenthal, A. S., Skoog, M., Eckner, R. J., Chou, T. C., Sabo, J. P., & Merluzzi, V. J. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.2.305 · Cited by 158
Self-citationSaag, M. S., Emini, E. A., Laskin, O. L., Douglas, J. A., Lapidus, W. I., Schleif, W. A., Whitley, R. J., HILDEBRAND, C. S., Byrnes, V. W., Kappes, J. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310073291502 · Cited by 156
Perrino, F. W., Preston, B. D., Sandell, L. J., & Loeb, L. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8343 · Cited by 153
Lenderking, W. R., Gelber, R. D., Cotton, D. J., Cole, B. F., Goldhirsch, A., Volberding, P. A., & Testa, M. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403173301102 · Cited by 153
Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro
Larder, B. A., Kellam, P., & Kemp, S. D. (1993) · Nature · doi:10.1038/365451a0 · Cited by 153
Self-citationReview of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design
Nanni, R. G., Ding, J., Jacobo‐Molina, A., Hughes, S. H., & Arnold, E. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171659 · Cited by 153
Klunder, J. M., Hargrave, K. D., WEST, M. L., Cullen, E., Pal, K., Behnke, M. L., Kapadia, S. R., McNeil, D. W., Wu, J. C., Chow, G. C., et al. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00088a027 · Cited by 151
Targeting HIV: antiretroviral therapy and development of drug resistance
Menéndez‐Arias, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02054-0 · Cited by 151
Eastman, P. S., Shapiro, D. E., Coombs, R. W., Frenkel, L. M., McSherry, G., Britto, P., Herman, S. A., & SPERLING, R. S. (1998) · The Journal of Infectious Diseases · doi:10.1086/514228 · Cited by 151
Pre–existence and emergence of drug resistance in HIV–1 infection
Bonhoeffer, S., & Martin, A. (1997) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1997.0089 · Cited by 150
Thomas, D. L., Cannon, R. O., Shapiro, C. N., Hook, E. W., Alter, M. J., & Quinn, T. C. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.5.990 · Cited by 149
A mechanistic theory to explain the efficacy of antiretroviral therapy
Laskey, S. B., & Siliciano, R. F. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3351 · Cited by 148
Parker, W. B., White, E. L., Shaddix, S. C., Ross, L. J., Buckheit, R. W., Germany, J., Secrist, J. A. I., Vince, R., & Shannon, W. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52360-7 · Cited by 148
Japour, A. J., Welles, S. L., D’Aquila, R. T., Johnson, V. A., Richman, D. D., Coombs, R. W., Reichelderfer, P. S., Kahn, J. O., Crumpacker, C. S., & Kuritzkes, D. R. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.5.1172 · Cited by 148
Self-citationSarafianos, S. G., Das, K., Hughes, S. H., & Arnold, E. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.10.013 · Cited by 147
Krebs, R., Immendoerfer, U., Thrall, S. H., Wöhrl, B. M., & Goody, R. S. (1997) · Biochemistry · doi:10.1021/bi970512z · Cited by 147
Chen, C., Banerjea, A. C., Harmison, G. G., Haglund, K. E., & Schubert, M. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.17.4581 · Cited by 145
Musicco, M., Lazzarin, A., Nicolosi, A., Gasparini, M., Costigliola, P., Arici, C., & Saracco, A. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.17.1971 · Cited by 143
Kempf, D. J., Marsh, K. C., Paul, D. A., Knigge, M. F., Norbeck, D. W., Kohlbrenner, W. E., Fino, L. C., Vasavanonda, S., Bryant, P., & Wang, X. C. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.11.2209 · Cited by 143
Learning Multiple Evolutionary Pathways from Cross-Sectional Data
Beerenwinkel, N., Rahnenführer, J., Däumer, M., Hoffmann, D. E., Kaiser, R., Selbig, J., & Lengauer, T. (2005) · Journal of Computational Biology · doi:10.1089/cmb.2005.12.584 · Cited by 142
Lacey, S. F., & Larder, B. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1428 · Cited by 142
Self-citationTriques, K., Bourgeois, A., Vidal, N., Mpoudi‐Ngolé, E., Mulanga-Kabeya, C., Nzilambi, N., Torimiro, N., Saman, E., Delaporte, É., & Peeters, M. (2000) · AIDS Research and Human Retroviruses · doi:10.1089/088922200309485 · Cited by 141
McMahon, J. B., Gulakowski, R. J., Weislow, O. S., Schultz, R. J., Narayanan, V. L., Clanton, D. J., Pedemonte, R. P., Wassmundt, F. W., Buckheit, R. W., & Decker, W. D. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.754 · Cited by 141
Clinical management of HIV-1 resistance
Paredes, R., & Clotet, B. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.015 · Cited by 140
Shirasaka, T., Yarchoan, R., O'Brien, M. C., Husson, R. N., Anderson, B. D., Kojima, E., Shimada, T., Broder, S., & Mitsuya, H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.562 · Cited by 139
Miles, S., Rt, M., Moreno, J. H., Baldwin, G. C., Alton, N. K., Souza, L., & Glaspy, J. A. (1991) · Blood · doi:10.1182/blood.v77.10.2109.2109 · Cited by 139
Gosselin, G., Schinazi, R. F., Sommadossi, J., Mathé, C., Bergogne, M. C., Aubertin, A.-M., Kirn, A., & IMBACH, J. ‐. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1292 · Cited by 137
Marcelin, A., Delaugerre, C., Wirden, M., Viegas, P., Simon, A., Katlama, C., & Cálvez, V. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10550 · Cited by 136
Hance, A. J., Lemiale, V., Izopet, J., Lecossier, D., Joly, V., Massip, P., Mammano, F., Descamps, D., Brun‐Vézinet, F., & Clavel, F. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6410-6417.2001 · Cited by 136
Johnson, V. A., Merrill, D. P., Videler, J. A., Chou, T., Byington, R. E., Eron, J. J., D’Aquila, R. T., & Hirsch, M. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.4.646 · Cited by 136
Überla, K., Stahl‐Hennig, C., Böttiger, D., Mätz‐Rensing, K., Kaup, F. ‐., Li, J., Haseltine, W. A., Fleckenstein, B. W., Hunsmann, G., & Öberg, B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8210 · Cited by 135
Jeong, L. S., Schinazi, R. F., Beach, J. W., Kim, H. O., Nampalli, S., Shanmuganathan, K., Alves, A. J., McMillan, A., Chu, C. K., & Mathis, R. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00054a001 · Cited by 135
Arts, E. J., & Wainberg, M. A. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.527 · Cited by 135
Evolutionary Dynamics of Complex Networks of HIV Drug-Resistant Strains: The Case of San Francisco
Smith, R. J., Okano, J. T., Kahn, J. S., Bodine, E. N., & Blower, S. M. (2010) · Science · doi:10.1126/science.1180556 · Cited by 134
Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals
Simon, V. R., Vanderhoeven, J., Hurley, A., Ramratnam, B., Louie, M. J., Dawson, K. M., Parkin, N. T., Boden, D., & Markowitz, M. H. (2002) · AIDS · doi:10.1097/00002030-200207260-00008 · Cited by 133
The effects of nucleoside analogs on telomerase and telomeres inTetrahymena
Strahl, C., & Blackburn, E. H. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.6.893 · Cited by 133
Kemp, S. D., Shi, C., Bloor, S., Harrigan, P. R., Mellors, J. W., & Larder, B. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5093-5098.1998 · Cited by 133
Self-citationComparisons of the Hbv and HIV Polymerase, and Antiviral Resistance Mutations
Bartholomeusz, A., Tehan, B. G., & Chalmers, D. K. (2004) · Antiviral Therapy · doi:10.1177/135965350400900203 · Cited by 132
Diaz, R. S., Sabino, É. C., Mayer, A. J., Mosley, J. W., & Busch, M. P. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3273-3281.1995 · Cited by 132
Yerly, S., Rakik, A., Loes, S. K., Hirschel, B. J., Descamps, D., Brun‐Vézinet, F., & Perrin, L. H. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.3520-3523.1998 · Cited by 132
Henderson, D. K., & Gerberding, J. L. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/160.2.321 · Cited by 132
Kozal, M. J., Shafer, R. W., Winters, M. A., Katzenstein, D. A., & Merigan, T. C. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.3.526 · Cited by 132
Schmit, J., Cogniaux, J., Hermans, P., VAECK, C. V., Sprecher, S., Remoortel, B. V., Witvrouw, M., Balzarini, J. M., Desmyter, J., Clercq, E. D., et al. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.5.962 · Cited by 131
Savarino, A., Lucia, M. B., Rastrelli, E., Rutella, S., Golotta, C., Morra, E., Tamburrini, E., Perno, C. F., Boelaert, J. R., Sperber, K. E., et al. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00002 · Cited by 130
Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians
Stein, D. S., & Moore, K. H. P. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.1.11.34439 · Cited by 130
Violin, M., Cozzi‐Lepri, A., Velleca, R., Vincenti, A., Delia, S., Chiodo, F., Ghinelli, F., Bertoli, A., Monforte, A. D., Perno, C. F., et al. (2004) · AIDS · doi:10.1097/00002030-200401230-00012 · Cited by 130
Lacey, S. F., Reardon, J. E., Furfine, E. S., Kunkel, T. A., Bębenek, K., Eckert, K. A., Kemp, S. D., & Larder, B. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49604-x · Cited by 130
Self-citationGoudsmit, J., de Ronde, A., de Rooij, E., & de Boer, R. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4479-4484.1997 · Cited by 129
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.